Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Eliglustat

An oral glucosylceramide synthase inhibitor for type 1 Gaucher disease: it reduces production of the lipid that builds up in cells and is a tablet alternative to intravenous infusions. Approved in the United States in 2014. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.

Did you know?It was born at the University of Michigan from an idea of neurochemist Norman Radin, later developed by nephrologist James Shayman: a project lasting about forty years before approval.

EliglustatGo to the active ingredient →
EliglustatActive ingredientEliglustatCat. No. P-E022-001CAS 491833-29-5

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.